Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Silence Therapeutics PLC Sponsored ADR (SLN) vs Zevra Therapeutics, Inc. (ZVRA)

Silence Therapeutics PLC Sponsored ADR and Zevra Therapeutics, Inc. are both Biotechnology companies. Silence Therapeutics PLC Sponsored ADR and Zevra Therapeutics, Inc. are of similar size ($697.3M and $668.7M). Silence Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 11.6×. Zevra Therapeutics, Inc. grew revenue faster over the last twelve months: 119.4% against −97.0%. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Zevra Therapeutics, Inc. leads on 14 and Silence Therapeutics PLC Sponsored ADR on 2.

Valuation

Metric SLN ZVRA Biotechnology median
P/E n/m 11.62 7.88
P/S 629.45 4.80 11.47
P/B 13.73 3.00 2.52
Price to free cash flow n/m 19.75 21.16
EV/EBITDA n/m 6.59 0.74
EV/Sales 543.65 3.90 10.73
Earnings yield (11.45%) 8.61% (28.84%)
Free cash flow yield (8.01%) 5.06% (23.03%)

Profitability

Metric SLN ZVRA Biotechnology median
Gross margin 79.50% 95.46% 65.16%
Operating margin 0.00% 60.54% 0.00%
Net margin 0.00% 42.25% 0.00%
Free cash flow margin 0.00% 24.30% 0.00%
Return on equity (90.41%) 34.33% (57.72%)
Return on assets (44.14%) 20.57% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLN ZVRA Biotechnology median
Revenue growth (TTM) (96.97%) 119.40% 5.64%
EPS growth (last fiscal year) (90.91%) 159.21% —
Revenue growth, 5-year CAGR (39.74%) 51.62% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLN ZVRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.42 5.17 4.73
Net debt to EBITDA 0.94 39.03 0.96

Dividend

Metric SLN ZVRA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric SLN ZVRA Biotechnology median
Market cap 697.32m 668.66m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack